Capillary Technologies Approves Acquisition of Session For $20 Million

Capillary Technologies, a SaaS firm, has approved an investment through its wholly owned overseas subsidiary to acquire US-based loyalty and engagement platform Session M Inc., according to a regulatory filing on Tuesday.
The company’s board has sanctioned an investment in Capillary Pte. Ltd. to acquire 100% equity in Session M, currently a wholly owned subsidiary of Mastercard Inc. The deal will also include Session M’s Czech subsidiary. The acquisition is structured with a base cash consideration of $20 million and is expected to close within 180 days from signing, subject to customary conditions.
About Session M
Founded in 2011, Session M provides a cloud-based loyalty and customer engagement platform serving global enterprises. The company recorded revenues of $50.5 million in CY2025, down from $54.5 million in CY2024 and $57 million in CY2023, showing a gradual decline over the past three years.
Capillary Technologies’ Financial Performance
On the financial front, Capillary Technologies’ revenue from operations grew 16% year-on-year to ₹184 crore in Q3 FY26. However, net profit declined 20% to ₹8 crore during the same period.
By the end of trading today, the company’s shares stood at ₹512, giving it a total market capitalisation of ₹4,067 crore (approximately $447 million). Capillary Technologies made a subdued debut on the stock market on November 21, 2025. Its shares were listed at ₹560 on the BSE, a 3% discount to the issue price of ₹577, while on the NSE, the stock opened slightly higher at ₹571.9.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 25, 2026, 11:25 AM IST

Sachin Gupta
- RPG Life Sciences Share Price Crashes Over 10% After Q2 FY27 Results
- ACME Solar Share in Focus as Subsidiary Collaborates with NTPC on 400 MW Renewable Energy Project
- Hikal Share Price Gains Over 8%; Achieves Swissmedic GMP Certification for Bengaluru Facility
- Sun Pharma Share Price Gains Nearly 2%; Secures FDA Approval for ILUMYA in Treating Psoriatic Arthritis
- Best Long-Term Stocks in November 2026 Based on 5 Year CAGR: BSE, Adani Power and More




